Chemical Structure (Aricept 01)
Aricept Tablet, Film Coated
Product Images NDC 62856-247
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Aricept (NDC 62856-247). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eisai Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Aricept 02)
Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas Cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Aricept 03)
Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Aricept 04)
Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Aricept 05)
Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Aricept 06)
Cumulative percentage of patients from two different groups (Aricept 10 mg/day and Aricept 5 mg/day) was evaluated based on a patient's cognitive state (measured by ADAS-Cog) and global improvement in their condition. The table includes scores at 7, 4, and 2 points, with a change in ADAS-Cog scores and total improvement percentages reported. The text does not provide any additional information.*
Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Aricept 07)
This appears to be a graph showing the percentage of patients taking Aricept 10 mg/day, Aricept 5 mg/day, and Plscevo, with a breakdown of their CIBIC-plus Rating improvements. It is not possible to provide more information without additional context or data.*
Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Aricept 08)
This text appears to be a graphical representation of the change from baseline of the SIB (Severe Impairment Battery) score for participants taking Aricept 10mg/day versus placebo over a period of 3 months. No further information is available in the text provided.*
Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Aricept 09)
Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Aricept 0a)
Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Aricept 0b)
Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Aricept 0c)
Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Aricept 0d)
Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Aricept 0e)
This is a table showing the percentage of patients who experienced improvement, worsening, or no change in their CIBIC-plus Rating while taking either Aricept 23 mg/day or Aricept 10 mg/day. There is no specific data shown in the table.*
Ndc 62856-245-30aricept® 5(donepezil HCl Tablets)5 mg30 Tablets (Aricept 0f)
Aricept is a medication containing 5 mg donepezil hydrochloride that is distributed by Eisai Inc. The recommended storage temperature is 25°C (77°F) with permitted excursions from 15°C-30°C (58°F-86°F). It is advised to dispense the medication in tight containers, following USP standards. For dosage and use information, consult the accompanying prescribing information. Lot/exp and serialization information is included on the package.*
Ndc 62856-246-30aricept® 10(donepezil HCl Tablets)10 mg30 Tablets (Aricept 10)
This is a prescription drug called Aricept that contains 10mg of donepezil hydrochloride per tablet. It should be stored at 25°C (77°F) with permitted excursions to 15°C-30°C (59°F-86°F) and dispensed in tight containers. Additional information is available in the accompanying prescribing information. This drug is distributed by Eisai Inc. in Nutley, NJ and this particular package contains 30 tablets. Lot and expiration information are indicated along with a serialization area.*
Ndc 62856-247-30aricept®donepezil HCl23 mg30 Tablets (Aricept 11)
This text describes the storage conditions and dosage information of Donepezil Hydrochloride tablets in a 30-tablet container. The tablets contain 23mg of the drug and should be stored at 25°C (77°F), with permissible excursions between 15°C-30°C (9°F-86°F). The tablets are to be dispensed in tight containers and prescription information is available with the product. The tablets are only available through prescription and distributed by Eisai Inc. The manufacturing of the product occurred in Japan.*
Ndc 62856-831-30aricept® Odt™(donepezil HCl) 5 mgorally Disintegrating Tablets (Aricept 12)
ARICEPT 001 is a medication for oral administration that comes in the form of orally disintegrating tablets. The active ingredient is donepezil hydrochloride, and each tablet contains 5 mg of this compound. The packaging suggests reading the instructions on the package before use.*
Ndc 62856-832-30aricept® Odt™(donepezil HCl) 10 mgorally Disintegrating Tablets (Aricept 13)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
